Insurance Coverage Lags as Cancer Science, Treatment Move Forward
“Brain cancer” or “H4 G34-mutant”? As knowledge about genetics advances, some doctors say cancers should be defined by their mutations, not the tissues where they manifest.
Drug Costs
1-20 of 704 results
-
-
With Midterms Looming, Journalists Consider Measles, Food Recalls, and Obamacare
KFF Health News journalists made the rounds on national and local media recently to discuss topical stories. Here’s a collection of their appearances.
-
The Medicare GLP-1 Discount Has One Big Catch: Some Sick Patients Don’t Qualify
The new Medicare GLP-1 Bridge program promises eligible beneficiaries access to popular weight loss drugs for as little as $50 a month. But for some, having the very medical conditions these drugs are approved to treat means they don't qualify for the discount.
-
Watch: Mark Cuban Says You Can’t Fix Healthcare Until Every Price Is Known
With his online pharmacy, Mark Cuban changed how generic drugs are sold — and he has thoughts about how to fix the healthcare system. The billionaire businessman talks to KFF Health News’ Julie Rovner to answer the question: “How Would You Fix It?”
By Julie Rovner and Hannah Norman -
How Much of a Cancer Drug Is Too Much? Patients, Researchers Challenge FDA-Approved Dosages
Patients and researchers point to evidence that many cancer drug dosages are excessive, and that reducing the amount and frequency could save billions of dollars and prevent some of the worst side effects.
By Arthur Allen -
Newsom Promotes Affordable Insulin, but California’s Generic Label Off to a Slow Start
California is the first to launch state-branded insulin as Gov. Gavin Newsom tries to disrupt the pharmaceutical industry. But the new CalRx drug label has been slow to reach pharmacies and patients.
By Angela Hart -
Watch: GOP Senator Says Trump’s Tariffs Could Mean Safer Drugs — For a Price
Bill Cassidy of Louisiana chairs the Senate’s health committee. In an interview with KFF Health News’ Julie Rovner, he discusses the drug supply, his proposal to defray out-of-pocket costs, and his controversial vote to confirm Robert F. Kennedy Jr. as health secretary.
By Julie Rovner and Hannah Norman -
Copay Assistance Is Meant To Defray Patient Drug Costs. Some Insurers Keep It Instead.
Drugmakers provide financial assistance to help patients afford increasingly expensive medications. But some insurers do not count those payments toward a plan’s deductible or out-of-pocket maximum and make patients pay instead.
By Daniel Chang -
Thousands of Medicare Beneficiaries Thought Their Drug Plan Was Free. Then They Lost It.
Thousands of people who had a Medicare drug plan with zero-dollar premiums last year got small premium increases this year — and didn’t know it. They were dropped from their coverage for failing to pay amounts as little as $8, and most can’t get it again until 2027.
By Susan Jaffe -
She Struggled To Get a Lifesaving Drug Even After Insurers Vowed To Help
Margaret Hvatum ended up in the hospital after her insurer denied coverage of a medicine she relies on to boost her immune system. Hvatum got entangled in the preapproval process, which the insurance industry has vowed to improve.
-
Trouble Getting Weight Loss Drugs Covered by Insurance? Here’s What To Know
If your doctor prescribes a GLP-1 medication for weight loss but your insurance won’t cover it, you have options.
-
Telehealth Booms as Demand for GLP-1s Surges and Questions Mount About Safety, Oversight
Many telehealth companies have emerged in recent years offering easy access to GLP-1 weight loss drugs as demand has exploded. Meanwhile, researchers and doctors are concerned that some of these online companies aren't properly screening or monitoring patients. “It gives a black eye to telemedicine,” one researcher said.
By Lauren Sausser and Maia Rosenfeld -
Trump Bought Stock in Eli Lilly as His Policies Gave the Drugmaker a Big Boost, Documents Show
Get our weekly newsletter, The Week in Brief, featuring a roundup of our original coverage, Fridays at 2 p.m. ET.
By Darius Tahir -
Journalists Unpack Latest on Vaccines, Vaping, and TrumpRx
KFF Health News journalists made the rounds on national media recently to discuss topical stories. Here’s a collection of their appearances.
-
Trump Promised Cheaper Drugs. Some Prices Dropped. Many Others Shot Up.
For all of President Donald Trump’s showmanship, the share of Americans his policies will likely help remains slim, even if some patients do come out ahead.
By Elisabeth Rosenthal and Arthur Allen -
That Discount at the Pharmacy Counter May Pack Hidden Costs
The new TrumpRx program relies partly on connecting consumers with discount coupons offered by drugmakers. For insured patients, though, using a coupon can prove dicey.
-
A New Medicare Option for Weight Loss Drugs: What Older Americans Should Know
It may soon get easier for millions of people with Medicare to get discounted GLP-1 drugs for weight loss.
The Supreme Court Case That Could Slow Generic Drugs
Season 15, Episode 6In “Hikma v. Amarin,” the Supreme Court’s decision could affect how quickly generic versions of brand-name medicines come to market.
Abortion Pills, the Budget, and RFK Jr.
Episode 441This week, the Trump administration won a court battle to delay a ruling on access to the abortion pill mifepristone, angering its own anti-abortion allies. Meanwhile, the president’s budget arrived on Capitol Hill, where lawmakers are unlikely to agree to its proposed cuts to Health and Human Services programs. Lauren Weber of The Washington Post, Alice Miranda Ollstein of Politico, and Maya Goldman of Axios join KFF Health News’ Julie Rovner to discuss these stories and more.
New Flu Vax? FDA Says No Thanks
Episode 433It’s been a busy week at the FDA, with a political appointee overruling agency scientists to reject an application for a new flu vaccine. Meanwhile, anti-abortion Republicans on Capitol Hill complain the agency is dragging its feet on reviewing the abortion pill mifepristone. Jackie Fortiér of KFF Health News, Lizzy Lawrence of Stat, and Alice Miranda Ollstein of Politico join KFF Health News’ Julie Rovner to discuss these stories and more.